Pressure BioSciences, Inc. Launches Novel Protein Extraction Kit for Lipid- Rich Samples at the 67th American Diabetes Association Meeting
WEST BRIDGEWATER, Mass., June 25 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that it has launched its first pressure cycling technology (PCT)-dependent research-use only kit. Called ProteoSolveLRS, the kit is intended to help the thousands of scientists worldwide who have the difficult task of extracting proteins from important lipid-rich samples. ProteoSolveLRS was launched on Saturday, June 23rd at the 67th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois.
On June 6, 2007, PBI announced the development of a novel, potentially revolutionary PCT-dependent method for the safe, rapid, efficient, and reproducible extraction of proteins from lipid-rich samples, including adipose and brain tissues, organelles, and membrane preparations. Proteomic analysis of such samples is widely used in the study of diabetes, cancer, ALS, heart disease, and a number of other serious human disorders related to obesity. The Company believes that its PCT-dependent method of protein extraction from lipid-rich samples offers significant advantages over current extraction techniques, especially the ability to use certain organic solvents instead of harsh detergents in the extraction process.
The Company believes that obesity is an epidemic clinical condition directly related to roughly 300,000 deaths per year in the US, and associated with an increased risk for a number of serious health conditions, particularly diabetes. A recent study by the National Changing Diabetes Program (NCDP) indicated that 18 of 21 US federal agencies had a budgetary influence impact on diabetes, that one out of eight US federal health care dollars is spent treating people with diabetes, and that of the $645 billion estimated in total US health care spending in 2005, the US spent approximately 12%, or $79.7 billion, related to diabetes. The study's research team suggested that there were "many missed opportunities for the federal government to enhance its impact on diabetes prevention, detection, treatment, and management of complications."
Dr. Nathan P. Lawrence, Vice President of Marketing and Sales of PBI, said: "ProteoSolveLRS combines specific buffers, solvents, PULSE Tubes (PCT processing vials), and instructions in a single box ("kit"). All the researcher needs to do is to purchase or lease the Barocycler instrument and purchase the kit from PBI and they will have everything they need to enhance their protein extraction from lipid-rich samples."
Mr. Richard T. Schumacher, Founder, President, and CEO of PBI, commented: "We strongly believe that our novel, patent-pending, PCT-dependent method for the detergent-free extraction of proteins from lipid-rich samples will benefit the thousands of researchers around the world who are working on new approaches for the prevention, detection, and treatment of diseases related to obesity, including diabetes, heart disease, stroke, and cancer. As recently announced, we are aggressively expanding our sales team and other sales capabilities at this time. Over the coming months, we plan to focus a majority of these additional capabilities in areas of research where lipid- rich samples are currently being used, as we believe that these areas offer tremendous potential for a significant return on investment for PBI."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded, early-stage company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio- molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.
Forward Looking Statements
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements include statements regarding the use of the Company's Pressure Cycling Technology Sample Preparation System (PCT SPS) for the extraction of proteins from lipid- rich samples; that the use of the Company's PCT SPS with certain organic solvents may obviate the need to use detergents in the extraction of proteins from lipid-rich samples; that the Company's extraction method offers significant advantages over current techniques for the extraction of proteins from lipid-rich, biological materials; that the Company's extraction method will benefit researchers around the world; and the Company's planned expansion of its sales team and other sales capabilities. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of the PCT technology; due to unforeseen technical, marketing, sales, and distribution difficulties, PBI may not have sufficient financial resources to finance the commercialization of PCT as currently planned; due to such unforeseen technical, marketing, sales, and distribution difficulties, the PCT-dependent, detergent-free method of protein extraction may not offer any advantages over current methods of protein extraction; that the PCT-dependent, detergent-free method of protein extraction may not be adopted by the scientific community as an accepted method of protein extraction; that the PCT-dependent, detergent-free method of protein extraction may not help advance diabetes and other scientific research; that the Company may not be successful in expanding its sales team and other sales capabilities as planned; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, the Company's Quarterly Report on Form 10-QSB for the quarter ended March 31, 2007, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
Visit us at our website http://www.pressurebiosciences.com
Investor Contacts:
Richard T. Schumacher, President & CEO
Edward H. Myles, Sr. Vice President of Finance & CFO (508) 580-1818 (T)
SOURCE Pressure BioSciences, Inc.
Released June 25, 2007